The general office of China’s National Medical Products Administration published a draft implementation measure on drug market exclusivity periods on 19 October 2026, with feedback open until 18 November 2026. It attaches a one-year exclusivity to a marketed medicine that adds, for the first time in China, a pediatric indication, a child-appropriate dosage form or a child-appropriate strength — the commercial reward behind oral solutions, granules and low-dose presentations reaching the domestic market rather than children being dosed down from adult products. For an international family arriving in Shanghai, that points to more pediatric-specific formats and rare-disease indications becoming locally available over the following years, but the draft’s effective date is still blank, so nothing here changes what your child can be prescribed on a visit planned now.
What was published on 19 October
The general office of China’s National Medical Products Administration released a draft implementation measure on drug market exclusivity periods — 《药品市场独占期实施办法（征求意见稿）》 — on 19 October 2026, according to a report published on Tencent News on 20 October 2026. On the pediatric side it is the first time China’s drug regulator has proposed a fixed period of protected market exclusivity as the commercial reward for children’s medicines and rare-disease medicines, with different terms attached to different routes to market.
Two procedural details should be read before the incentives. Written feedback on the draft is open before 18 November 2026, to the mailbox the report lists as [email protected], with the subject line marked as feedback on the drug market exclusivity implementation measure. And the commencement clause is still empty: the draft prints “本办法自 起施行”, leaving the effective date blank. A rule with no start date is a proposal, not a change that applies to any medicine prescribed this month. The published report does not specify how the product categories are defined in detail, any transitional arrangements, or an approval timeline for individual products.
The exclusivity terms as the draft sets them out
The report lists the proposed terms by product category and route to market. Read the table as a description of incentives aimed at manufacturers, not as a list of medicines that become available to patients.
| Category as reported | Route to market in the draft | Proposed exclusivity |
|---|---|---|
| Pediatric medicines | An innovative drug, or an originator product already marketed outside China, launched inside China | 2 years |
| Pediatric medicines | A marketed medicine adds, for the first time in China, a pediatric indication, a new child-appropriate dosage form or a new child-appropriate strength | 1 year |
| Rare-disease medicines | An innovative drug, or an originator product already marketed abroad, launched in China | 7 years |
| Rare-disease medicines | An improved new drug | 5 years |
| Rare-disease medicines | A generic or biological product for a rare-disease medicine already marketed abroad, first launched in China; or the first China addition of a rare-disease indication already approved abroad | 4 years |
Why one year on a dosage form matters more than it sounds
Exclusivity is a commercial instrument, not a clinical one. What the draft changes is the return a manufacturer can expect on work that is slow and expensive: developing and registering a presentation actually made for children — an oral solution, a granule, a lower strength — instead of relying on an adult product that has to be divided down. A defined period of protected sales is the element that makes that investment recoverable, which is why the shortest term in the draft, one year, is arguably the one with the most direct effect on a child’s prescription.
That mechanism addresses a gap international families meet routinely. When only an adult presentation exists locally, a prescription written in Shanghai may be filled in a different form, at a different strength, from the one used at home, and the practical answer is often to carry supply from the country of residence or to use a medicine outside its licensed indication. The published report names no company, no product and no launch date, so it cannot say which of those gaps closes or when; it explains why manufacturers would have a reason to fill one.
What an internationally arriving family can plan around
Treat the measure as background to a medium-term supply question. The near-term planning items for a visit are unchanged: build the medication list on ingredient names, current strengths and current forms; carry enough supply for the stay plus the interval before any refill can be arranged; and ask at the appointment which presentation is used locally and how the dose is expressed on the prescription.
- More pediatric-specific presentations and rare-disease indications would reach the Chinese market over the following years, not within this visit window.
- Conditions now managed with carried-in medicine or adult products used off-label may become locally prescribable — if a final rule is issued and a product later follows.
- Dose adjustment from adult forms and off-label prescribing will not disappear; both remain judgments for the examining pediatrician.
- A new approved presentation does not confirm that a named Shanghai hospital stocks it, prescribes it or prices it in a particular way.
- Nothing in the draft changes what your child can be prescribed, or what a hospital can dispense, on a trip arranged today.
Institution-level policy is not a decision about your child
This page reports a draft rule addressed to the pharmaceutical industry. It says nothing about any individual patient: not whether a medicine your child takes will gain a pediatric form, not whether a hospital will stock it, not whether a clinician would prescribe it, and not whether the rare-disease indication you are chasing is on any manufacturer’s development list. The draft carries no effective date, and the published report does not estimate how many products the measure would attract or in what period.
Where the draft does touch a family’s decision is indirect and time-shifted. If exclusivity periods are confirmed in a final text and manufacturers respond, the range of locally available pediatric presentations and rare-disease indications in Shanghai should widen over several years. Until a specific product exists and a hospital confirms it, the answer to “can we get this medicine here?” remains a question for the receiving clinical team and the hospital, not for a policy announcement.
Questions to put to the hospital and the clinical team
ChildMedCare cannot confirm a hospital’s formulary, pricing or prescribing practice from a regulatory draft, and publishes no dose guidance. Each item above needs a written answer from the hospital or from the clinical team that examines your child.
- Which presentation of this medicine do you prescribe here — solution, granule or tablet — and at which strength?
- How will the dose for this child be calculated and recorded, and can we have that in writing?
- Is the product on the hospital’s list, what does it cost, and how is it billed?
- If we must carry medicine from home, what documentation should travel with it?
- If a pediatric presentation is not stocked, what does the clinical team advise instead?
- Who should our local clinician contact after we return home, and in which language?
How this page was written
This is an editorial summary by a non-clinical editorial team, based on one dated report of a draft published by the National Medical Products Administration’s general office. ChildMedCare is not a hospital, is not the website of Shanghai Children’s Medical Center, does not speak for it, and does not represent any regulator; decisions about services, stocking and clinical pathways belong to each hospital’s own teams.
The checklist is a planning tool compiled by our editors for families to use before booking travel. It is not an admission, registration or prescribing requirement from any hospital, and any written hospital instruction takes precedence over it. Nothing here is clinical advice: whether a medicine, a dosage form or a dose is right for a particular child is a judgment for the licensed pediatric clinician who has examined that child.
Planning checklist
- Note the 18 Nov 2026 feedback deadline; the rule is still a draft.
- Ask whether a pediatric form exists here for each medicine.
- Bring ingredient names, current strengths and current forms.
- Carry enough supply for the stay plus the refill gap.
- Confirm stock, price and billing with the hospital in writing.
- Do not change any dose because of a regulatory announcement.
Sources & further reading
- NMPA发布《药品市场独占期实施办法（征求意见稿）》 ↗
Sole basis for this page: the Tencent News (药品圈) report of 20 October 2026. It supplies the release by the NMPA general office on 19 October 2026 of the draft implementation measure on drug market exclusivity periods; the feedback deadline before 18 November 2026 and the listed mailbox [email protected] with the required subject line; the pediatric terms of two years for an innovative drug or an originator product already marketed abroad launched in China, and one year for a marketed medicine adding a first-in-China pediatric indication, a new child-appropriate dosage form or a new child-appropriate strength; the rare-disease terms of seven years, five years for an improved new drug, and four years for a first-in-China generic or biological product for a rare-disease medicine already marketed abroad or a first addition of a rare-disease indication already approved abroad; and the blank effective-date clause printed as “本办法自 起施行”.
Sources checked November 3, 2026. Planning checklists are ChildMedCare editorial guidance; they are not hospital admission requirements.